BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
金曜日, 9 25

Tempest Therapeutics Inc

TPSTNASDAQ
Trade with Public
Trade with Public
$0.8500
-0.072-7.81%
近くで: Sep 24, 5:00 PM EST
$0.8626
0.01261.48%
時間外: 7:57 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較株式レポート

Tempest Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tempest Therapeutics (TPST).

Price Target Range — 9 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$27Upside to Avg. PT+3030.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026HC Wainwright & Co.Joseph PantginisPT CutBuy$11→$7
Jan 22, 2026HC Wainwright & Co.Joseph PantginisUpgradeNeutral→Buy$11
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target

HC Wainwright & Co. analyst Joseph Pantginis upgrades Tempest Therapeutics (NASDAQ:TPST) from Neutral to Buy and announces $11 price target.
Benzinga Newsdesk

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
Vandana Singh

PRO
Correction : Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Raises Price Target to $9 (Previous Target changed)

Correction: Scotiabank analyst George Farmer downgrades Tempest Therapeutics (NASDAQ:TPST) from Sector Outperform to Sector Perform and raises the price target from $7 to $9. (Previous Target changed)
Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:TPST) from Buy to Neutral and maintains the price target from $16 to $16.
Benzinga Newsdesk

PRO
Scotiabank Maintains Sector Outperform on Tempest Therapeutics, Lowers Price Target to $7

Scotiabank analyst George Farmer maintains Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform and lowers the price target from $13 to $7.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved